Allergy Therapeutics PLC Update to Grass MATA MPL Ph III clinical programme (6083U)
November 26 2019 - 1:01AM
UK Regulatory
TIDMAGY
RNS Number : 6083U
Allergy Therapeutics PLC
26 November 2019
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Allergy Therapeutics announces update to Grass MATA MPL phase
III clinical programme
26 November 2019 Allergy Therapeutics plc (AIM: AGY), the fully
integrated commercial biotechnology company specialising in allergy
vaccines, today provides an update on its Grass MATA MPL phase III
study, due to start in Autumn 2020.
Following further investigation of the phase III Birch MATA MPL
study (B301), the upcoming Grass study will now take a stepwise
approach, with two stages covering both the 2020/2021 and 2021/2022
pollen seasons, rather than the single large trial originally
planned for the 2020/2021 season.
The study's stepwise approach has been designed with input from
allergy experts. It enables a phase III-scale study to begin in the
2020/2021 season, followed by an interim review to gain insights
into the trial, before continuing to the second part of the
study.
Results from the Group's successful G205 phase II clinical
study, which completed in 2018, evaluating the dose to be taken
into phase III, were recently published in the World Allergy
Organisation Journal. The paper "Strong dose response after
immunotherapy with PQ grass using conjunctival provocation testing"
reports that the immunotherapy demonstrated a highly statistically
significant (p<0.0001), monotonic dose response for all
pre-specified models, which has enabled the Group to acquire
agreement from regulatory authorities in Europe and the USA on a
target dose for the phase III clinical programme.
Manuel Llobet, CEO of Allergy Therapeutics, said: "The planning
for our Grass MATA MPL phase III study is now completed and we look
forward to starting this important trial."
This announcement contains inside information for the purposes
of Article 7 of Regulatory (EU) No.596/2014
- ENDS -
References
Zielen et al. Strong dose response after immunotherapy with PQ
grass using conjunctival provocation testing. World Allergy
Organization Journal (2019) 12:100075
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Erik Anderson, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third-party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development include vaccines for grass, tree and house
dust mite, and peanut allergy vaccine in pre-clinical development.
Other adjuvant systems to boost performance of vaccines outside
allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESBABLTMBBTBLL
(END) Dow Jones Newswires
November 26, 2019 02:00 ET (07:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024